Femasys

Femasys Inventory

The Inventory of Femasys (FEMY) as of Oct 21, 2026 is 5.74 M USD. In the previous year, Inventory was 3.05 M USD — a change of 88.43% (higher).

Inventory

5.74 MUSD

YoY

88.43%

Last updated:

Inventory of Femasys is 2025 5.74 M USD. Inventory of Femasys was 2024 3.05 M USD. It decreases by 88.43% higher compared to the previous year.

The Femasys Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2019
172,497.00 USD
Jan 1, 2020
131,378.00 USD
Jan 1, 2021
208,270.00 USD
Jan 1, 2022
436,723.00 USD
Jan 1, 2023
667,118.00 USD
Jan 1, 2024
3.05 M USD
Jan 1, 2025
5.74 M USD
The Femasys Inventory history
YEARInventoryYoY
5.74 MUSD+88.43%
3.05 MUSD+356.64%
667,118.00USD+52.76%
436,723.00USD+109.69%
208,270.00USD+58.53%
131,378.00USD-23.84%
172,497.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Femasys Stock analysis

What does Femasys do? Femasys, Inc. generates revenue through the development and commercialization of its two lead product candidates, FemBloc and FemaSeed, alongside its FemEMB technology platform. FemBloc, a permanent birth control solution featuring dual intrauterine directional delivery with a degradable biopolymer, targets women seeking non-surgical contraceptive options. FemaSeed, an artificial insemination infertility treatment with single intrauterine directional delivery, addresses fertility challenges for patients. The FemEMB platform, designed for tissue sampling in physician offices, complements these products by enhancing diagnostic capabilities for women's health. These solutions are marketed to healthcare providers and clinics globally, focusing on improving patient care and health economics through office-based, non-surgical interventions. The company's revenue streams are derived from the sale of FemBloc, FemaSeed, and FemEMB to medical institutions and healthcare professionals. FemBloc targets women requiring permanent contraception, while FemaSeed serves patients with infertility issues. FemEMB supports physicians in conducting tissue sampling during routine office visits. The firm’s focus on non-surgical, office-based solutions positions it to serve a growing segment of women seeking accessible reproductive healthcare without invasive procedures. This approach aligns with the company’s mission to improve health economics by reducing the need for hospital-based interventions. Femasys, Inc. leverages its product portfolio to address key reproductive health needs through innovative, non-surgical technologies. FemBloc and FemaSeed are positioned as advanced alternatives to traditional methods, offering targeted delivery systems for contraception and fertility treatment. The FemEMB platform further enhances the company’s offerings by integrating diagnostic tools into standard office care. These products are sold to healthcare providers who serve women worldwide, emphasizing accessibility and improved patient outcomes. The company’s strategy centers on delivering solutions that meet the evolving demands of women’s healthcare in a cost-effective manner. Femasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Femasys stock

Inventory of Femasys is 5.74 M USD in 2025.

Inventory of Femasys changed from 3.05 M USD to 5.74 M USD, representing a 88.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Femasys since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Femasys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Femasys

All Key Metrics — Femasys